Published in Med J Aust on March 03, 2003
Screening injecting drug users for sexually transmitted infections and blood borne viruses using street outreach and self collected sampling. Sex Transm Infect (2005) 0.98
Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase. Med J Aust (2003) 0.75
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Relation between HIV viral load and infectiousness: a model-based analysis. Lancet (2008) 5.74
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet (2006) 4.45
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr (2005) 3.18
Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin Infect Dis (2009) 2.89
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis (2011) 2.08
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis (2012) 2.01
Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS (2002) 1.98
The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int J Epidemiol (2003) 1.78
Importance of promoting HIV testing for preventing secondary transmissions: modelling the Australian HIV epidemic among men who have sex with men. Sex Health (2009) 1.70
Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS (2014) 1.59
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS (2007) 1.49
Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol (2006) 1.45
Suicide risk among recently released prisoners in New South Wales, Australia. Med J Aust (2007) 1.28
An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025. Liver Int (2008) 1.23
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS (2010) 1.23
Factors associated with mortality in a cohort of Australian prisoners. Eur J Epidemiol (2007) 1.18
AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS (2009) 1.17
Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr (2009) 1.16
Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther (2005) 1.14
Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy. PLoS One (2012) 1.14
Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS (2012) 1.11
Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog (2008) 1.10
Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. AIDS (2011) 1.08
Risk factors and causes of death in the Australian HIV Observational Database. Sex Health (2006) 1.07
The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. J Acquir Immune Defic Syndr (2009) 1.04
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Int AIDS Soc (2012) 1.03
Modeling trends in HIV incidence among homosexual men in Australia 1995-2006. J Acquir Immune Defic Syndr (2004) 1.00
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. AIDS (2005) 0.97
Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database. BMC Infect Dis (2010) 0.97
Cancer incidence in a Nationwide HIV/AIDS patient cohort in Taiwan in 1998-2009. J Acquir Immune Defic Syndr (2014) 0.96
The safety of candidate vaginal microbicides since nonoxynol-9: a systematic review of published studies. AIDS (2009) 0.95
Loss to Followup in HIV-Infected Patients from Asia-Pacific Region: Results from TAHOD. AIDS Res Treat (2012) 0.95
Cancers in the TREAT Asia HIV Observational Database (TAHOD): a retrospective analysis of risk factors. J Int AIDS Soc (2010) 0.94
Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis. J Gastroenterol Hepatol (2007) 0.94
Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' FcgammaRIIa genotype. AIDS (2010) 0.94
Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol (2011) 0.93
Hospitalizations in a cohort of HIV patients in Australia, 1999-2007. AIDS (2010) 0.93
Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex Health (2007) 0.92
Epidemiology of hepatitis C virus infection in Australia. Aust Fam Physician (2003) 0.92
The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006. J Gastroenterol Hepatol (2009) 0.92
The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin. BMC Endocr Disord (2005) 0.91
Rapidly ageing HIV epidemic among men who have sex with men in Australia. Sex Health (2009) 0.91
Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. J Int AIDS Soc (2012) 0.90
The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. J Hepatol (2003) 0.90
Loss to follow-up in the Australian HIV Observational Database. Antivir Ther (2014) 0.89
The potential impact of new generation molecular point-of-care tests on gonorrhoea and chlamydia in a setting of high endemic prevalence. Sex Health (2013) 0.89
Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression. AIDS Res Hum Retroviruses (2009) 0.87
CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts. J Acquir Immune Defic Syndr (2011) 0.87
Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Aust (2011) 0.87
Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLoS One (2010) 0.87
STI in remote communities: improved and enhanced primary health care (STRIVE) study protocol: a cluster randomised controlled trial comparing 'usual practice' STI care to enhanced care in remote primary health care services in Australia. BMC Infect Dis (2013) 0.85
Modelling HIV incidence in gay men: increased treatment, unsafe sex and sexually transmissible infections. AIDS (2002) 0.85
Using mathematical modelling to help explain the differential increase in HIV incidence in New South Wales, Victoria and Queensland: importance of other sexually transmissible infections. Sex Health (2008) 0.84
Hepatitis C treatment outcomes in Australian clinics. Med J Aust (2012) 0.84
A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study. PLoS Clin Trials (2006) 0.84
Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol (2010) 0.84
Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males. Sex Transm Dis (2013) 0.83
Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. AIDS (2012) 0.82
Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries. J Gastroenterol Hepatol (2007) 0.82
High viral fitness during acute HIV-1 infection. PLoS One (2010) 0.82
Difference in absolute CD4+ count according to CD4 percentage between Asian and Caucasian HIV-infected patients. J AIDS Clin Res (2010) 0.82
Relationship between CD4 cell count and serious long-term complications among HIV-positive individuals. Curr Opin HIV AIDS (2014) 0.82
Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection. Vaccine (2013) 0.81
Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study. BMC Public Health (2011) 0.80
Cholestasis associated with the use of pravastatin sodium. Med J Aust (2002) 0.80
Recent trends in early stage response to combination antiretroviral therapy in Australia. Antivir Ther (2014) 0.79
Population movement can sustain STI prevalence in remote Australian indigenous communities. BMC Infect Dis (2013) 0.79
Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection. Med J Aust (2002) 0.79
Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia. J Gastroenterol Hepatol (2008) 0.78
The impact of wild-type reversion on transmitted resistance surveillance. Antivir Ther (2014) 0.78
Involuntary treatment of drug and alcohol dependence in New South Wales: an old Act and a new direction. Med J Aust (2013) 0.78
Changes in metabolic, inflammatory and coagulation biomarkers after HIV seroconversion--the Health in Men (HIM) Biomarker Substudy. Antivir Ther (2012) 0.78
Smoking, alcohol and illicit drug use effects on survival in HIV-positive persons. Curr Opin HIV AIDS (2016) 0.78
Hospital-related morbidity in people notified with hepatitis C: a population-based record linkage study in New South Wales, Australia. J Hepatol (2010) 0.77
The medical complications of alcohol use: understanding mechanisms to improve management. Drug Alcohol Rev (2005) 0.76
Hospitalization for Anxiety and Mood Disorders in HIV-Infected and -Uninfected Gay and Bisexual Men. J Acquir Immune Defic Syndr (2016) 0.75
The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models. BMC Infect Dis (2013) 0.75
Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust (2007) 0.75
Australia's first religiously affiliated medical school. Med J Aust (2005) 0.75
HIV and Aging: Demographic Change in the Asia-Pacific Region. J Acquir Immune Defic Syndr (2017) 0.75
Problem-based learning: a dissemination success story? Med J Aust (2006) 0.75
A clinical prediction tool for targeted pre-antiretroviral therapy creatinine testing applied to the TREAT Asia HIV observational database cohort. J Acquir Immune Defic Syndr (2014) 0.75
Relationship between hyperglycemia and the risk of tuberculosis in Asian HIV-positive individuals in the antiretroviral therapy era: cohort study. J Acquir Immune Defic Syndr (2014) 0.75
Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region. J Antivir Antiretrovir (2009) 0.75
Predictors and outcomes of HIV-infected antiretroviral-naive patients with discordant responses to combination antiretroviral treatment in Asian and Australian populations: results from APHOD. J Acquir Immune Defic Syndr (2011) 0.75
Causes of death in hepatitis B and C: a methodological issue. Lancet (2007) 0.75
Loss to Follow-up Trends in HIV-Positive Patients Receiving Antiretroviral Treatment in Asia From 2003 to 2013. J Acquir Immune Defic Syndr (2017) 0.75
Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort. Hepatol Res (2012) 0.75
Hepatitis C: where are we at and where are we going? Med J Aust (2002) 0.75
First line antiretroviral treatment outcomes and durability in HIV-infectedchildren treatedthrough theuniversal coverage health program in Thailand. J Acquir Immune Defic Syndr (2017) 0.75
Funding antiretroviral treatment for HIV-positive temporary residents in Australia prevents transmission and is inexpensive. Sex Health (2017) 0.75
Comparison of central and local HIV-1 RNA quantification from two international clinical trials. AIDS (2014) 0.75
First-Line Antiretroviral Treatment Outcomes and Durability in HIV-Infected Children Treated Through the Universal Coverage Health Program in Thailand. J Acquir Immune Defic Syndr (2017) 0.75